The application of Foxp3+Treg and PDL1+(CD274+) NEUT in the diagnosis, prognostic risk prediction, transplantation immune monitoring and tolerance of of HCC and liver transplantation: a real world study

Studies on the mechanisms of Foxp3+Treg and PDL1+(CD274+) NEUT in immune tolerance and immune escape of liver cancer and liver transplantation

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000041292

Enrollment

Unknown

Registered

2020-12-23

Start date

2021-01-02

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Cirrhosis, Hepatocellular carcinoma

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Preoperative imaging suggested liver malignant tumor; Postoperative pathological findings suggested HCC or intrahepatic cholangiocarcinoma (ICC); (2) Ages 30-65 years; (3) Informed consent.

Exclusion criteria

Exclusion criteria: (1) Lung, bone and other distant metastasis; (2) Patients with severe cardiopulmonary diseases cannot tolerate surgery; (3) Patients with HCV and ALD diseases.

Design outcomes

Primary

Measure	Time frame
Foxp3+Treg;PDL1+NEUT;DFS;OS;	—

Secondary

Measure	Time frame
CD8+Treg;cytokines;NLR;rejection;recurrence time;drug concentration;	—

Countries

China

Contacts

Public ContactLin Zhou

commander_fmmu@126.com+86 15652757208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026